A controlled entry point for early-stage European founders seeking to scale their technologies in the world's biggest healthcare economy.
On February 12, 2026, Northwestern Medicine and London-based Founders Factory announced a transatlantic accelerator designed to shepherd European AI healthcare startups into the American market — one of the most guarded and consequential in the world. The partnership reflects a maturing recognition that innovation in medicine no longer respects national borders, and that the distance between a promising prototype and a life-saving deployment is often measured not in technology, but in trust and access. By opening its hospitals, physicians, and clinical networks to early-stage founders, Northwestern is wagering that the institutions best positioned to shape the future of care are those willing to help build it.
- European AI startups face a near-impenetrable wall entering U.S. healthcare — American hospitals are deeply cautious about adopting technologies from unfamiliar international teams, making credibility the scarcest resource for foreign founders.
- The stakes are not abstract: clinical AI, properly deployed, could prevent an estimated 250,000 deaths globally by 2030, and over 40 percent of AI-discovered drugs already rely on AI-assisted trial platforms — numbers that are forcing hospital boards to move.
- Northwestern Medicine is offering something almost impossible to obtain otherwise — direct, embedded access to 11 hospitals, 5,400+ physicians, and 200+ outpatient sites across Chicago, including a flagship institution ranked among America's best for 14 consecutive years.
- The four-month program pairs clinical immersion with commercial mentorship, a residential week in Chicago, and connections to The London Clinic, turning a transatlantic partnership into a structured runway for pre-Series A companies.
- Applications closed March 31, 2026, with the program already signaling a broader shift: rather than waiting for startups to prove themselves elsewhere first, Northwestern is volunteering to be part of the proof — accepting risk in exchange for first access to emerging technologies.
On February 12, 2026, Northwestern Medicine and Founders Factory announced a new accelerator program designed to bring European artificial intelligence startups directly into the American healthcare market. The partnership joins one of the Midwest's largest health systems with a London-based accelerator that has backed over 450 companies and facilitated more than 500 enterprise pilots since 2015.
The program's core offer is access — the kind that money alone cannot buy. Selected startups spend four months working alongside Northwestern Medicine's clinical and commercial teams, gaining entry to 11 hospitals, more than 5,400 affiliated physicians, and over 200 outpatient and diagnostic sites across the Chicago area. Northwestern Memorial Hospital, the system's flagship, has appeared on U.S. News and World Report's Best Hospital Honor Roll for 14 consecutive years. For a pre-Series A company trying to validate its technology in a real healthcare environment, this institutional footprint is nearly unattainable through conventional channels. The program also connects founders with The London Clinic, Northwestern's UK partner, extending the collaboration across the Atlantic.
The timing is deliberate. Artificial intelligence is actively reshaping how hospitals detect disease, manage chronic conditions, and accelerate drug discovery. Health policy estimates suggest that properly deployed clinical AI could prevent around 250,000 deaths globally by 2030 — figures that have moved innovation from a strategic aspiration to an operational priority for hospital leadership.
Founders Factory brings geographic reach and sector credibility to the arrangement, operating from London, New York, Berlin, Milan, Perth, and Singapore. The accelerator focuses on health, deeptech, and fintech — fields where regulatory complexity typically slows market entry — and has been recognized as the United Kingdom's leading startup hub.
Douglas King, Northwestern Medicine's Chief Digital and Information Officer, described the collaboration as a bridge between world-class European talent and one of America's leading academic health systems. The language is precise: Northwestern is positioning itself as a development partner, not merely a customer. Founders will spend a residential week in Chicago embedded with clinical teams, working through the practical questions that separate a promising prototype from a deployable solution.
For Founders Factory's portfolio, the arrangement removes what would otherwise be the most stubborn obstacle to American expansion — not capital, but credibility. For Northwestern, it offers first access to emerging technologies and the ability to shape how they take root. Applications closed March 31, 2026, with the program representing a quiet but significant bet that the institutions most likely to define the future of care are those willing to help build it.
Northwestern Medicine and Founders Factory announced a new accelerator program on February 12, 2026, designed to fast-track European artificial intelligence startups into the American healthcare market. The partnership pairs one of the Midwest's largest health systems with a London-based startup accelerator, creating what amounts to a controlled entry point for early-stage European founders seeking to test and scale their technologies in the world's biggest healthcare economy.
The mechanics are straightforward but significant. Selected startups will spend four months working directly with Northwestern Medicine's clinical and commercial teams, gaining access to 11 hospitals, more than 5,400 affiliated physicians, and over 200 outpatient and diagnostic sites across the Chicago area. Northwestern Memorial Hospital, the system's flagship institution, has landed on U.S. News and World Report's Best Hospital Honor Roll for 14 consecutive years. For a pre-Series A company trying to prove its technology works in a real healthcare setting, this kind of institutional access is nearly impossible to obtain otherwise. The program also connects founders with The London Clinic, Northwestern Medicine's UK partner, extending the collaboration across the Atlantic.
The timing reflects a genuine shift in how healthcare institutions approach innovation. Artificial intelligence is no longer a theoretical tool in medicine—it's reshaping how hospitals detect disease, manage chronic conditions, and accelerate drug discovery. Industry data cited in the announcement suggests that over 40 percent of AI-discovered drugs currently rely on AI-assisted trial platforms in their early stages. More broadly, clinical AI deployed properly could prevent around 250,000 deaths globally by 2030, according to health policy estimates. These aren't marginal improvements. They're the kind of numbers that move hospital boards to action.
Founders Factory, which has backed over 450 technology companies since 2015 and facilitated more than 500 enterprise pilots for its portfolio companies, brings operational credibility to the arrangement. The accelerator operates from London, New York, Berlin, Milan, Perth, and Singapore, positioning it as a genuine bridge between European innovation and American markets. London itself ranks among the world's top three startup ecosystems, and Founders Factory has been recognized as the United Kingdom's leading startup hub. The organization focuses on health, deeptech, industrial transformation, and fintech—sectors where regulatory complexity and capital requirements typically slow market entry.
Douglas King, Northwestern Medicine's Chief Digital and Information Officer, framed the partnership as an extension of the health system's existing commitment to innovation. "This collaboration with Founders Factory creates a powerful bridge between world-class European talent and one of America's leading academic health systems," he said. The language matters: Northwestern is positioning itself not as a vendor or customer, but as an active partner in the development process. Startups selected for the program will spend a residential week in Chicago, embedded with clinical teams, working through the practical questions that separate a promising prototype from a deployable solution.
Applications opened immediately, with a deadline of March 31, 2026. The program targets pre-Series A ventures—companies that have typically raised seed funding and demonstrated some form of product-market fit, but haven't yet secured the larger institutional capital that comes with Series A rounds. For these founders, the barrier to entering the U.S. healthcare market is not primarily financial; it's access and credibility. American hospitals are cautious about adopting new technologies, particularly from unfamiliar international teams. An accelerator program that provides both clinical validation and operational mentorship addresses that friction directly.
The partnership also signals something broader about how American healthcare institutions are thinking about innovation in 2026. Rather than waiting for startups to prove themselves in other markets first, Northwestern Medicine is essentially volunteering to be part of the proof. This approach carries risk—not every startup will succeed, and not every technology will integrate smoothly into existing workflows. But it also positions Northwestern as an early adopter, giving the health system first look at emerging technologies and the ability to shape how they're implemented. For Founders Factory, the arrangement de-risks the American market entry for its portfolio, removing what would otherwise be a major obstacle to scaling European innovations in the world's largest healthcare economy.
Citas Notables
This collaboration with Founders Factory creates a powerful bridge between world-class European talent and one of America's leading academic health systems.— Doug King, Chief Digital and Information Officer, Northwestern Medicine
By teaming up with Northwestern, one of America's top medical institutions, we are de-risking entry into the world's biggest healthcare market for UK and European startups.— Founders Factory
La Conversación del Hearth Otra perspectiva de la historia
Why would a major American health system volunteer to work with unproven startups? That seems like it adds complexity to their operations.
It does add complexity, but the calculus has shifted. Healthcare systems are under constant pressure to improve outcomes and reduce costs. If an AI tool can genuinely help with either of those things, the cost of testing it—especially with institutional support—is lower than the cost of missing out on the innovation entirely.
So this is about Northwestern positioning itself as an innovator, not just a provider?
Partly that, yes. But it's also practical. They get first access to technologies that might eventually reshape their operations. They're not just helping European founders; they're building a pipeline of solutions they can evaluate before anyone else.
What makes European startups different from American ones in this space?
Different regulatory environment, different funding structures, different problems they've been solving. London and the EU have been pushing hard on AI in healthcare for years. Some of these founders have already worked through regulatory questions that American startups are still figuring out.
And the four-month timeline—is that realistic for actually testing something in a hospital?
It's tight, but it's not about full deployment. It's about proving the concept works in a real clinical setting, identifying what needs to change, and building relationships with the people who would actually use it. That's often the hardest part.
Who really wins here—the startups or Northwestern?
Both, but differently. The startups get institutional credibility and real-world validation. Northwestern gets early access to innovations and the ability to shape how they're implemented. The real winner is probably the patient, if any of these technologies actually work.